A PRACTICAL EXPERIENCE OF EFFICIENT USAGE OF CORDAFLEX-RETARD IN OUT-PATIENTS WITH ESSENTIAL HYPERTENSION

Abstract

We have studied clinical efficacy and safety of a II generation calcium antagonist cordaflex-retard administered in a daily dose of 40 mg for 4 weeks to 40 patients with essential hypertension. Efficacy was estimated by clinical BP measuring and daily monitoring. The results indicate BP decrease in an overwhelming majority of patients. Treatment with cordaflex did not deteriorate daily BP rhythm, did not increase its variability. Adverse reactions were noted in a minor number of patients and did not require drug withdrawal as they were mild.

Keywords

• arterial hypertension
• daily blood pressure monitoring
• cordaflex-retard